Novo Nordisk’s NovoRapid and Levemir found to significantly reduce severe hypoglycaemia

Novo Nordisk's short-acting and long-acting modern insulin analogues NovoRapid (insulin aspart) and Levemir (insulin detemir) have significantly reduced severe hypoglycaemia in people with type 1 diabetes compared to human insulin (regular/NPH), acco…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news